Recent study identifies CD30 expression across 17 tumor types
In a study of over 1,500 patients with nonlymphomatous malignancies, 17 different diagnoses were associated with varying degrees of CD30 expression. These data are from an interim analysis of an ongoing study.View more >
CD30 expression may differentiate variants of Burkitt lymphoma
25% of Burkitt lymphoma cases express CD30. The endemic variant, African Burkitt lymphoma, uniformly expresses CD30 (N = 5). This suggests there may be important pathological differences between the subtypes.View more >
CD30 expression and overall survival are inversely associated in PTCL‑NOS
A recent study found that CD30 expression is an adverse predictor of survival in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and is less common in Lennert lymphoma than in other variants of PTCL-NOS.View more >
CD30 screening aids in differential diagnosis of germ cell tumors
CD30 is strongly expressed in more than 95% of embryonal carcinomas, while other germ cell tumors lack CD30. An antibody panel using CD30 in combination with KIT can be used to differentiate embryonal carcinoma from other tumors of germ cell origin.View more >
CD30 can be detected using diverse methodologies
CD30 expression can be analyzed using immunohistochemistry on fixed tissue or flow cytometry on live cells. Click here to learn more about CD30 detection and view representative images from clinical case studies.View more >
Dedicated to advancing understanding of CD30
Synonyms: Ki-1, Ki-1 antigen, TNFRSF8 (tumor necrosis factor receptor superfamily member 8), D1S166E (gene: CD30 is the protein encoded by this gene).
After nearly 3 decades of investigation, much has been learned about the CD30 cell surface antigen, but much more remains to be elucidated. The Science of CD30 project will provide an overview of what is known about CD30, with an emphasis on cell surface expression, and will also outline areas for future research. Your ideas are welcome. As progress is made, new discussions, articles, videos and links will be added to update this site, maintaining Science of CD30 as an active forum for expanding the knowledge base on the properties, expression and pathophysiologic role of this antigen. Please check back frequently to keep abreast of advances and updates.